← Oncology Approval Tracker

FDA DECISION ·

Calquence + Venclexta

acalabrutinib with venetoclax · AstraZeneca / AbbVie / Genentech

FDA approvalNew or expanded indicationCLL / SLL
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, using either approved acalabrutinib tablets or capsules with venetoclax.

LAMPGEN ANALYSIS

Why it matters

This provides a fixed-duration BTK and BCL-2 inhibitor combination. AMPLIFY studied previously untreated patients without del(17p) or TP53 mutation, which is relevant when applying the trial evidence.

What research teams should watch

Plan for venetoclax ramp-up, tumor lysis risk assessment and lab timing. Report the molecular exclusions separately from the approved use.

PRIMARY RECORDS

Sources